Medicine Advances最新文献

{"title":"Thoracic dumbbell giant schwannoma in a young woman: A case report","authors":"Zheng Jun,&nbsp;Yu Bing,&nbsp;Li Qing Song","doi":"10.1002/med4.30","DOIUrl":"https://doi.org/10.1002/med4.30","url":null,"abstract":"<p>Schwannomas, which are benign, are one of the most common intraspinal tumors, accounting for 29% of primary spinal tumors. Schwannomas have several other names, including neurinoma, neurilemmoma, and neuroma. They originate from Schwann cells, which were first described by Theodor Schwann, a German physiologist, biologist, and histologist. Here, we present a patient with a giant, thoracic, dumbbell-shaped schwannoma. This benign tumor protruded into the subcutaneous fascial layer, compressing the pleura and the left side of the thoracic spinal cord. Additionally, some of the spinous processes and laminae of the thoracic vertebrae were missing. Most patients with this type of tumor are asymptomatic; however, up to 11.7% of patients have symptoms that depend on the size and location of the tumor. Magnetic resonance imaging can accurately determine the extent of the tumor and any intraspinal component and is thus helpful in selecting the optimal surgical procedure.</p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.30","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50155682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Data mining analysis of professor Qiu Changlin's Chinese Medicinal therapy for Parkinson's disease","authors":"Shuang Wu,&nbsp;Han Wu,&nbsp;Xuhong Jiang,&nbsp;Hongchen Li,&nbsp;Jie Luo","doi":"10.1002/med4.28","DOIUrl":"https://doi.org/10.1002/med4.28","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Parkinson's disease (PD) is a prevalent, progressive neurodegenerative disease that has been widely treated using dopamine replacement therapy. However, this therapy does not prevent the progressive loss of dopaminergic neurons in the substantia nigra pars compacta. Clinical experience has shown that Chinese medicines (CMs) can alleviate the side effects of Western medicines for PD and improve the quality of life of patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This paper describes the collection and analysis of Professor Qiu Changlin's decoctions for PD and proposes new ideas on the Law of CM Clinical Formula Administration and Syndrome Differentiation of PD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A database of Professor Qiu's prescriptions for PD patients of Zhejiang Provincial Hospital of Chinese Medicine over 5 years (January 2018 to May 2022) was established and analyzed using Microsoft Excel 2019 and SPSS Modeler 22.0.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Frequency analysis of 1162 prescriptions comprising 232 CMs revealed 17 high-frequency CMs, including Shu Di Huang (Rehmanniae Radix Praeparata) and Chao Bai Shao (Paeoniae Radix Alba), and correlations among the CMs. The property (nature) of these CMs is warm, and the flavors are mainly bitter, sweet, and sour. Most enter the liver meridian. Based on cluster analysis, we obtained a core effective prescription that mainly comprises Tian Ma, Gou Teng Yin and Zuo Gui Wan.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The core effective prescription is expected to inspire new ideas for the administration of CM clinical formulas and syndrome differentiation in PD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.28","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50155673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acceptance of encapsulated porcine islet xenotransplantation by patients and doctors in the US","authors":"Shinichi Matsumoto,&nbsp;Noriaki Yamamoto","doi":"10.1002/med4.29","DOIUrl":"https://doi.org/10.1002/med4.29","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Previously, we performed encapsulated porcine islet xenotransplantation for the treatment of unstable type 1 diabetic patients and demonstrated the clinical benefit and safety in New Zealand and Argentina. Conversely, the treatment of type 1 diabetes differs from country to country; therefore, understanding the acceptance of the new treatment by patients and medical doctors in each country is important. In this study, a survey study of the acceptance of the encapsulated porcine islet xenotransplantation by the type 1 diabetic patients and medical doctors in the US was conducted.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The questionnaires consisted of the acceptance of the encapsulated porcine islet xenotransplantation without immunosuppression, and the reasons for selecting and not selecting. Moreover, we conducted a sub-analysis among patient groups regarding severe hypoglycemia and HbA1c levels.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The majority of patients and doctors (patients, 63.8%; doctors, 70.0%) had a positive opinion to accept this treatment. A significantly high number of doctors selected no immunosuppression for selecting this treatment (patients, 35.5%; doctors, 53.6%; <i>p</i> &lt; 0.001), and a significantly high number of patients selected not insulin free for not selecting this treatment (patients 20.4%, doctors 12.4%, <i>p</i> &lt; 0.05). The high HbA1c group had the highest ‘definitely’ accept rate, which was significantly higher than those of the other HbA1c groups (High HbA1c group, 50.0%; other HbA1c groups, 22.2%; <i>p</i> &lt; 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In conclusion, the majority of US patients and doctors had positive opinions to accept the encapsulated porcine islet xenotransplantation. Type 1 diabetic patients with high HbA1c levels had the highest ‘definitely’ acceptance rates.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.29","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50124587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Crosstalk between cancer cells and the nervous system","authors":"Meng Huang,&nbsp;Gu Gong,&nbsp;Yicheng Deng,&nbsp;Xinmiao Long,&nbsp;Wenyong Long,&nbsp;Qing Liu,&nbsp;Wei Zhao,&nbsp;Rufu Chen","doi":"10.1002/med4.27","DOIUrl":"https://doi.org/10.1002/med4.27","url":null,"abstract":"<p>Crosstalk between tumors and the nervous system has emerged as a significant hallmark of human cancer. In the central nervous system, neurons closely interact with tumor cells, promoting the proliferation of glioma and neuroblastoma. Additionally, the peripheral nervous system plays a crucial role in reshaping the tumor microenvironment, modulating angiogenesis, and regulating immune cell function, while also directly promoting tumorigenesis and metastasis. Current research has elucidated some of the specific neural signaling mechanisms involved in this crosstalk, including neurotransmitters, neuropeptides, and growth factors. In this review, we aim to summarize these mechanisms and highlight the latest discoveries in various solid tumors, such as glioma, pancreatic, prostate, and gastrointestinal cancers. By understanding the intricate crosstalk between cancer cells and the nervous system, we can develop more effective and targeted treatments for cancer patients.</p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.27","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50141962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"XRCC1, ABCB1, CYP3A5 and GSTP1 gene polymorphism associated with platinum-based drugs induced hematotoxicity in Chinese oesophageal cancer patients","authors":"Shuang Chen,&nbsp;Xiao Xiao,&nbsp;Jianliang Chen,&nbsp;Yun Chen,&nbsp;Zixian Wang,&nbsp;Guodong Qiu,&nbsp;Shuyao Zhang,&nbsp;Shilong Zhong","doi":"10.1002/med4.22","DOIUrl":"https://doi.org/10.1002/med4.22","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Hematotoxicity, including severe myelosuppression, is a common adverse drug reaction (ADR) during platinum-based treatment for oesophageal cancer (EC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>The aim of this study was to identify single-nucleotide polymorphisms (SNPs) associated with platinum-induced hematotoxicity in patients with EC, as the relationship between SNPs and this ADR is incompletely demonstrated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 262 patients receiving platinum-based chemotherapy (cisplatin, nedaplatin, carboplatin and oxaliplatin) were enrolled in this study. Ten SNPs in eight genes were genotyped via multiplex polymerase chain reaction and sequenced to evaluate their relationship with severe myelosuppression and its subset of leukopenia and neutropenia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Multivariate logistic analysis of cisplatin cohort in severe leukopenia group showed an odds ratio (OR) of GG + GA <i>versus</i> AA in <i>ABCB1</i> rs1045642 was 5.83 (95% confidence interval (CI) 1.63–20.83, <i>p</i> = 0.007, false discovery rate (FDR) = 0.028), while the OR of AA <i>versus</i> AG + GG in rs1128503 was 0.34 (95% CI 0.14–0.86, <i>p</i> = 0.022, FDR = 0.044). In nedaplatin cohort of neutropenia group, the OR of AA <i>versus</i> GG, AA + AG <i>versus</i> GG in <i>GSTP1</i> rs1695 was 10.34 (95% CI 1.71–62.40, <i>p</i> = 0.011, FDR = 0.040) and 7.48 (95% CI 1.37–40.81, <i>p</i> = 0.020, FDR = 0.040) respectively. <i>XRCC1</i> rs1799782 GG genotype in nedaplatin cohort of myelosuppression group and <i>CYP3A5</i> rs776746 CT genotype in nedaplatin cohort of severe leukopenia group and platinum cohorts of all groups appeared to be risk factors with the <i>p</i> values less than 0.05, but FDR values were all greater than 0.05.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study identified SNPs of <i>XRCC1</i>, <i>ABCB1</i>, <i>CYP3A5</i> and <i>GSTP1</i> related to hematotoxicity of platinum-based drugs, thereby providing a novel theoretical basis for the prediction and prevention of ADRs in platinum-based chemotherapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.22","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50146993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood immune inflammatory indicators predict prognosis in patients with coronary artery disease","authors":"Ju-E Liu,&nbsp;Shufen Zheng,&nbsp;Kai Chen,&nbsp;Jing Wang,&nbsp;Xiaoqi Liu,&nbsp;Weihua Lai,&nbsp;Qian Zhu,&nbsp;Zhuoyi Wu,&nbsp;Jinxiu Meng,&nbsp;Shuang Xia,&nbsp;Yong Liu,&nbsp;Shilong Zhong","doi":"10.1002/med4.24","DOIUrl":"https://doi.org/10.1002/med4.24","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The relationship between the combined hematological parameters and echocardiography and long-term prognosis in patients with coronary artery disease (CAD) remains unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We examined the ability of hematological parameters to predict all-cause death and major adverse cardiovascular events (MACE) based on Lasso Cox regression analysis. The significant predictors of hematological parameters from the Lasso Cox model were analyzed via multivariate Cox regression analysis and by adjusting for echocardiographic data. We calculated the continuous net reclassification improvement (cNRI) and integrated discrimination improvement (IDI) of the hematological parameters to assess the improvement in prediction.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A low hemoglobin and lymphocyte ratio and high hematocrit, red blood cell distribution width-coefficient of variation, and monocyte ratio significantly increased the risk of MACE and death in CAD patients. Neutrophil-to-lymphocyte ratio was associated with MACE but not death in CAD patients. After adjustment for echocardiographic parameters, hemoglobin, hematocrit, and lymphocyte ratio remained independently related to death and MACE. The addition of hematological and echocardiographic parameters to the Framingham risk score model significantly improved the area under the curve of mortality (0.794 <i>vs</i>. 0.713, <i>p</i> = 0.0007) and reclassification with cNRI of 30.6% (<i>p</i> = 0.002) and IDI of 0.055 (<i>p</i> &lt; 0.001). Mendelian randomization analyses identified that fibrinogen and neutrophil-to-lymphocyte ratio were associated with increased brain natriuretic peptide and decreased left ventricular ejection fraction.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These findings suggest that the blood immune inflammatory indicators fibrinogen and neutrophil-to-lymphocyte ratio were causally associated with the risk of heart failure after CAD. The combination of hematological biomarkers and echocardiography parameters as predictor variables is a useful predictive tool for all-cause mortality in patients with CAD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.24","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50142820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clarification to “Expert consensus on treatment for stage III non-small cell lung cancer”","authors":"","doi":"10.1002/med4.25","DOIUrl":"https://doi.org/10.1002/med4.25","url":null,"abstract":"<p>Wu YL, Lu S, Zhou QH, Zhang L, Cheng Y, Wang J, Wang BH, Hu CP, Lin LZ, Zhong WZ, Song Y, Yang N, Dong XR, Zhao J, Yang HH, Guo H, Yan XL, Liu HX, Ma R, Lin J, Liu SY, Chen C, Wang LF, Zhou CZ, Zhou M, Wu F, Yang XN, Du YY, Yao Y, Shao Y, Hong SD, Cui JW, Quan XP, Chen RR, Wu JY, Zhang JT, Zhou JY, Wang BC, Cheng C, Wang HJ, Liu JJ, Wu L, Huang Y, Kuang YK, Zhang YC, Hu J, Yang JJ, Feng WN, Su WM, Fan Y, Yang F, Chen M, Tang KJ, Tang Y, Shen P, Liu AW, Zhang HB, Liang WH, Zhou Q, Ma ZY, Cai XY, Liu H, Chen LF, Chuai SK, Chuai JZ, Zheng YF, You CX, Zhu XX, Li L, Zhang TM, Tu HY, Lin WR, Zhang XC, Zhou PH, Ke ZF, Liang HY. Expert consensus on treatment for stage III non-small cell lung cancer. Med. Adv. 2023;1:3–13.</p><p>We want to clarify that this article was originally published in Chinese in the <i>Journal of Evidence-based Medicine</i> (doi: 10.12019/j.issn.1671-5144.2022.03.001). This is an English translation of the original article and permission was granted by the <i>Journal of Evidence-based Medicine</i>.</p><p>The online version of the original article can be found at http://www.jebm.cn/CN/10.12019/j.issn.1671-5144.2022.03.001.</p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.25","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50154001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complex interplay between the immune system, metabolism, and epigenetic factors in autoimmune liver diseases","authors":"Ya-Fei Xu,&nbsp;Zhi-Bin Zhao,&nbsp;Ethan P. Yan,&nbsp;Zhe-Xiong Lian,&nbsp;Weici Zhang","doi":"10.1002/med4.23","DOIUrl":"https://doi.org/10.1002/med4.23","url":null,"abstract":"<p>Autoimmune liver diseases (ALDs) are chronic inflammatory hepatobiliary diseases in which the autoimmune responses directed against liver tissue result in inflammation and tissue damage. There are several types of ALDs, including autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, immunoglobulin G4-related sclerosing cholangitis, and overlap syndromes. Metabolism and epigenetics are both critical components of the development and progression of ALDs. Immunometabolism addresses how metabolic processes influence immune cell development, fate and behavior, and how immune responses impact metabolism. In the context of immunity, epigenetics involves regulating gene expression without altering the DNA sequence. Epigenetic modifications can ultimately result in changes in the immunophenotype. The interplay between the immune system, metabolism, and epigenetic factors is highly complex. A better understanding of this interplay and the regulatory mechanisms involved is crucial to uncover the disease pathogenesis of ALDs and exploring novel therapeutic options. This article provides a comprehensive review of the dysregulation of immunometabolism and epigenetics, as well as the multilevel regulatory mechanisms, underlying the autoimmunity in ALDs.</p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.23","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50140808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A glimpse of recent advances in the research of acute kidney injury","authors":"Zheng Dong,&nbsp;Xinling Liang","doi":"10.1002/med4.26","DOIUrl":"https://doi.org/10.1002/med4.26","url":null,"abstract":"<p>Acute kidney injury (AKI) is a major renal disease that affects 13 million people and is associated with almost 1.7 million deaths each year around the world. Previously referred to as acute renal failure, AKI is defined not only by a rapid functional decline of the kidney but also by pathological damages in kidney tissue. This updated definition contributes to modern renal medicine in at least two ways. First, the definition of AKI includes an early, preventable and treatable stage of the disease, which implies an urgent need for sensitive biomarkers for early diagnosis and treatment. Second, the AKI definition is proposed with clear criteria for diagnosis and severity grading, which are beneficial for clinical studies and the meta-analysis of different datasets.</p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.26","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50141270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in incidence and mortality of acute kidney disease following coronary angiography in Chinese population: 2008–2017","authors":"Qiang Li,&nbsp;Haozhang Huang,&nbsp;Weihua Chen,&nbsp;Shanshan Shi,&nbsp;Xiaozhao Lu,&nbsp;Wenguang Lai,&nbsp;Guoxiao Liang,&nbsp;Jielan Wu,&nbsp;Jiyan Chen,&nbsp;Jin Liu,&nbsp;Shiqun Chen,&nbsp;Amanda Y. Wang,&nbsp;Yong Liu","doi":"10.1002/med4.20","DOIUrl":"https://doi.org/10.1002/med4.20","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Acute kidney disease (AKD) has received increasing attention owing to its poor prognosis. However, few studies have investigated the trends in AKD incidence and prognosis among patients undergoing coronary angiography (CAG). Therefore, this study was designed to explore trends in the incidence and mortality of AKD following CAG in China.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We enrolled patients undergoing CAG using data of the Cardiorenal Improvement (CIN) cohort registry of Guangdong Provincial People's Hospital. Univariate and multivariate logistic regression analyses were applied to examine the incidence of AKD from 2008 to 2017. Mortality rates are presented as deaths per 1000 person-years and were evaluated in univariate and multivariate Cox regression analyses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 9665 patients (mean age: 61.6 ± 9.6 years, 40% women) were enrolled in the final analysis. From 2008 to 2017, the overall incidence and mortality of AKD were 19% and 323.0 per 1000 person-years, respectively. The incidence of AKD decreased from 25% to 13% during 2008–2017 (adjusted odds ratio, 0.40; 95% confidence interval [CI], 0.31–0.51; <i>p</i> &lt; 0.01; <i>p</i> for trend &lt;0.01). However, the mortality of AKD increased significantly from 138.2 to 544.1 per 1000 person-years (adjusted hazard ratio, 2.85; 95% CI, 1.20–6.73; <i>p</i> = 0.02, <i>p</i> for trend = 0.02). The above trends were observed consistently in patients stratified by sex and age.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our findings suggest a significant decrease in incidence and an increase in mortality of AKD following CAG from 2008 to 2017 in China. We advocate for more proactive measures to prevent AKD and improve the prognosis of patients with AKD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.20","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50152736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}